Yamagata K, Yamagata Y, Kobayashi M, et al. A long-term follow-up study of asymptomatic hematuria and/or proteinuria in adults. Clin Nephrol. 1996;45:281–8.
Iseki K, Iseki C, Ikemiya Y, et al. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996;49:800–5.
Iseki K. Evidence for asymptomatic microhematuria as a risk factor for the development of ESRD. Am J Kidney Dis. 2012;60:12–4.
Japanese Urological Association. Practice guidelines of bladder cancer 2019 (in Japanese). Tokyo: Igakutosho Shuppan; 2019.
Yamagata K, Takahashi H, Tomida C, et al. Prognosis of asymptomatic hematuria and/or proteinuria in men. High prevalence of IgA nephropathy among proteinuric patients found in mass screening. Nephron. 2002;91:34–42.
Chow KM, Kwan BC, Li PK, et al. Asymptomatic isolated microscopic haematuria: Long-term follow-up. QJM. 2004;97:739–45.
Horie S, Ito S, Okada H, et al. Japanese guidelines of the management of hematuria 2013. Clin Exp Nephrol. 2014;18:679–89.
Vivante A, Afek A, Frenkel-Nir Y, et al. Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease. JAMA. 2011;306:729–36.
Iseki K, Konta T, Asahi K, et al. Association of dipstick hematuria with all-cause mortality in the general population: results from the specific health check and guidance program in Japan. Nephrol Dial Transplant. 2018;33:825–32.
Iseki K, Konta T, Asahi K, et al. Higher cardiovascular mortality in men with persistent dipstick hematuria. Clin Exp Nephrol. 2020;25:1–7.
Linder BJ, Bass EJ, Mostafid H, et al. Guideline of guidelines: asymptomatic microscopic haematuria. BJU Int. 2018;121:176–83.
Wollin T, Laroche B, Psooy K. Canadian guidelines for the management of asymptomatic microscopic hematuria in adults. Can Urol Assoc J. 2009;3:77–80.
Davis R, Jones JS, Barocas DA, et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol. 2012;188:2473–81.
Kohro T, Furui Y, Mitsutake N, et al. The Japanese national health screening and intervention program aimed at preventing worsening of the metabolic syndrome. Int Heart J. 2008;49:193–203.
Ministry of Health, Labour and Welfare. Heisei 27 nendo tokutei kenko shinsatokutei hoken shidono jisshi jyokyo ni tsuite. 2017. https://www.mhlw.go.jp/stf/houdou/0000173038.html. Accessed October 23, 2020.
Kannno M, Okushi Y. Comparison of judgment rates before and after specific medical examination (in Japanese). Health Eval Promot. 2010;37:143.
Yamashita M. Urine sediment examination (in Japanese). Med Technol. 2011;910–5.
Murakami S, Igarashi T, Hara S, et al. Strategies for asymptomatic microscopic hematuria: a prospective study of 1,034 patients. J Urol. 1990;144:99–101.
Mishina T. Clinical study of 824 cases of microscopic hematuria (in Japanese). Jpn J Clin Urol. 1993;47:131–5.
Terasaki T. Imaging and renal biopsy results in screening for adult diseases (in Japanese). Prev Nephrol Urol. 1994;2:36–9.
Iseki K, Miyasato F, Uehara H, et al. Outcome study of renal biopsy patients in Okinawa. Japan Kidney Int. 2004;66:914–9.
Hoshino Y, Kaga T, Abe Y, et al. Renal biopsy findings and clinical indicators of patients with hematuria without overt proteinuria. Clin Exp Nephrol. 2015;19:918–24.
Yokoyama H, Sugiyama H, Sato H, et al. Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012;16:903–20.
Okonogi H, Kawamura T, Joh K, et al. A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity. Clin Exp Nephrol. 2019;23:16–25.
Matsuo S, Kawamura T, Jyo K. Clinical guides for IgA nephropathy in Japan, third version (in Japanese). Nihon Jinzo Gakkai Shi. 2011;53:123–35.
Cancer Information Service, National Cancer Center Japan. National Cancer Registry data provision for researcher. https://ganjoho.jp/med_pro/cancer_control/can_reg/national/datause/researcher.html. Accessed 26 Nov 2020
Cancer registration committee of the Japanese Urological Association. The report of clinical statistical studies on registered bladder cancer patients in japan 2002 (in Japanese). Nippon Hinyokika Gakkai Zasshi. 2013;1–19
National Cancer Center Japan. The cancer registry report of the nationwide designated cancer care hospitals. 2016. https://ganjoho.jp/public/qa_links/report/hosp_c/pdf/2016_report.pdf. Accessed 26 Nov 2020
Endo M. Epidemiology, symptoms and prognosis of IgA nephropathy (in Japanese). Nihon Jinzo Gakkai Shi. 2008;50:442–7.
Kato T. Primary care for kidney disease (in Japanese). Nippon Naika Gakkai Zasshi. 2001;90:1231–5.
Hattori R, Matsuura O, Takeuchi N, et al. Clinical importance of microhematuria as an initial sign of bladder tumor (in Japanese). Nippon Hinyokika Gakkai Zasshi. 1990;81:414–9.
Tanaka S, Ninomiya T, Katafuchi R, et al. The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy. Clin Exp Nephrol. 2016;20:689–98.
Komatsu H, Kikuchi M, Nakagawa H, et al. Long-term survival of patients with IgA nephropathy after dialysis therapy. Kidney Blood Press Res. 2013;37:649–56.
Ministry of Health, Labour and Welfare. Vital statistics of Japan 2015. Health and Welfare Statistics Association, Tokyo, 2017.
Kikuchi E, Fujimoto H, Mizutani Y, et al. Clinical outcome of tumor recurrence for ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999–2001 report from the Japanese urological association. Int J Urol. 2009;16:279–86.
Japanese Association of Clinical Cancer Centers. Zengankyo kameishiesetsuno seizonritsu kyodotyosa. http://www.zengankyo.ncc.go.jp/etc/seizonritsu/seizonritsu2011.html. Accessed November 26, 2020.
Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
Neumann PJ, Sanders GD, Russell LB, et al. Cost-effectiveness in health and medicine. 2nd ed. New York: Oxford University Press; 2016.
Tajima R, Kondo M, Kai H, et al. Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D). Clin Exp Nephrol. 2010;14:340–8.
Takura T, Nakanishi T, Kawanishi H, et al. Cost-effectiveness of maintenance hemodialysis in Japan. Ther Apher Dial. 2015;19:441–9.
Heijnsdijk EAM, Nieboer D, Garg T, et al. Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer. BJU Int. 2019;123:307–12.
Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19:422–37.
Bradley MS, Willis-Gray MG, Amundsen CL, et al. Microhematuria in postmenopausal women: adherence to guidelines in a tertiary care setting. J Urol. 2016;195:937–41.
Committee on Gynecologic Practice, American Urogynecologic Society. Asymptomatic microscopic hematuria in women. Female Pelvic Med Reconstr Surg. 2017;23:228–31.
Sugimura K, Ikemoto SI, Kawashima H, et al. Microscopic hematuria as a screening marker for urinary tract malignancies. Int J Urol. 2001;8:1–5.
Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006;107:2173–9.
Boulware LE, Jaar BG, Tarver-Carr ME, et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA. 2003;290:3101–14.
Wang H, Yang L, Wang F, et al. Strategies and cost-effectiveness evaluation of persistent albuminuria screening among high-risk population of chronic kidney disease. BMC Nephrol. 2017;18:135.
Sutton AJ, Lamont JV, Evans RM, et al. An early analysis of the cost-effectiveness of a diagnostic classifier for risk stratification of haematuria patients (DCRSHP) compared to flexible cystoscopy in the diagnosis of bladder cancer. PLoS ONE. 2018;13:e0202796.
Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer. 2006;107:982–90.
Fiorentino M, Bolignano D, Tesar V, et al. Renal biopsy in 2015—from epidemiology to evidence-based indications. Am J Nephrol. 2016;43:1–19.